abusesaffiliationarrow-downarrow-leftarrow-rightarrow-upattack-typeburgerchevron-downchevron-leftchevron-rightchevron-upClock iconclosedeletedevelopment-povertydiscriminationdollardownloademailenvironmentexternal-linkfacebookfiltergenderglobegroupshealthC4067174-3DD9-4B9E-AD64-284FDAAE6338@1xinformation-outlineinformationinstagraminvestment-trade-globalisationissueslabourlanguagesShapeCombined Shapeline, chart, up, arrow, graphLinkedInlocationmap-pinminusnewsorganisationotheroverviewpluspreviewArtboard 185profilerefreshIconnewssearchsecurityPathStock downStock steadyStock uptagticktooltiptwitteruniversalityweb
Article

23 Sep 2024

Author:
João Camargo and Hans Van Sharen, Corporate Europe Observatory

Corporate Europe Observatory's report: Bayer's Toxic Trails

"Bayer's Toxic Trails", 23 September 2024

Corporate Europe Observatory takes a deep dive into the present – and... past – of the German agrochemical giant Bayer. Whether it’s over glyphosate, GMOs, or global warming, we follow the company’s trail of lobbying to reveal how it attempts to capture public policy to pursue its private interests. [The report's authors accuse Bayer of] maintaining monopolistic control of the seed and pesticide markets, fighting off regulatory challenges to its toxic products, allegedly trying to limit legal liability... Bayer's current top lobbying priorities for the European institutions [were allegedly] to derail the original ambitions of the European Green Deal...

Concerning new GMOs, in 2021 Bayer proposed “a new regulation (separate from GMOs) assessing whether the changes in the DNA of the new plant are similar to the ones that could have been obtained through conventional breeding methods or spontaneous mutation.” This would [allegedly] class new GMOs as... the same as non-GM products. In the same year Bayer [allegedly] clarified its opposition to an export ban on toxic chemicals and pesticides already banned in the EU, claiming that “an exclusive ban in the EU would only result in production being shifted to other regions." 

...Bayer has [allegedly] been lobbying lawmakers in three US states to pass legislation which would provide legal protection for the company from future lawsuits...

Privacy information

This site uses cookies and other web storage technologies. You can set your privacy choices below. Changes will take effect immediately.

For more information on our use of web storage, please refer to our Data Usage and Cookies Policy

Strictly necessary storage

ON
OFF

Necessary storage enables core site functionality. This site cannot function without it, so it can only be disabled by changing settings in your browser.

Analytics cookie

ON
OFF

When you access our website we use Google Analytics to collect information on your visit. Accepting this cookie will allow us to understand more details about your journey, and improve how we surface information. All analytics information is anonymous and we do not use it to identify you. Google provides a Google Analytics opt-out add on for all popular browsers.

Promotional cookies

ON
OFF

We share news and updates on business and human rights through third party platforms, including social media and search engines. These cookies help us to understand the performance of these promotions.

Your privacy choices for this site

This site uses cookies and other web storage technologies to enhance your experience beyond necessary core functionality.